Singapore-based Wave Life Sciences Ltd., a clinical-stage genetic medicine company, has developed a discovery and drug development platform called PRISM which enables it to design, optimize, and produce stereopure oligonucleotides. These oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore functional proteins production, or reduce the expression of disease-promoting RNAs or proteins. The company is working on a number of molecules including WVE-004 for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia, WVE-003 for the treatment of Huntington's disease and WVE-N531 for the treatment of Duchenne muscular dystrophy. Furthermore, it has several preclinical programs for CNS-related disorders, such as Alzheimer's and Parkinson's diseases. The company has also established collaboration agreements with Pfizer, Takeda Pharmaceutical Company, and Glaxo Group. Wave Life was incorporated in 2012.
WAVE Life Sciences Ltd.'s ticker is WVE
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 201-500 employees working at WAVE Life Sciences Ltd.
It is https://wavelifesciences.com/
WAVE Life Sciences Ltd. is in the Healthcare sector
WAVE Life Sciences Ltd. is in the Biotechnology industry
The following five companies are WAVE Life Sciences Ltd.'s industry peers: